Published in Cancer Res on January 12, 2010
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell (2012) 3.37
Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol (2011) 3.23
The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet (2014) 3.17
Human cancer long non-coding RNA transcriptomes. PLoS One (2011) 2.38
A distinct spectrum of copy number aberrations in pediatric high-grade gliomas. Clin Cancer Res (2010) 2.37
Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nat Rev Cancer (2014) 2.10
BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One (2011) 2.04
Mesenchymal transition and PDGFRA amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas. PLoS One (2012) 1.93
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res (2012) 1.92
Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin Cancer Res (2011) 1.80
Targeted therapy for BRAFV600E malignant astrocytoma. Clin Cancer Res (2011) 1.79
BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. J Clin Oncol (2015) 1.62
BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model. Clin Cancer Res (2011) 1.61
Paediatric and adult malignant glioma: close relatives or distant cousins? Nat Rev Clin Oncol (2012) 1.58
p53-Dependent induction of PVT1 and miR-1204. J Biol Chem (2011) 1.56
Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. Acta Neuropathol (2013) 1.54
PI3K/AKT pathway alterations are associated with clinically aggressive and histologically anaplastic subsets of pilocytic astrocytoma. Acta Neuropathol (2010) 1.47
Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc Natl Acad Sci U S A (2013) 1.33
MAPK pathway activation in pilocytic astrocytoma. Cell Mol Life Sci (2011) 1.28
Treatment of high-grade glioma in children and adolescents. Neuro Oncol (2011) 1.27
Genome-wide identification of genes with amplification and/or fusion in small cell lung cancer. Genes Chromosomes Cancer (2013) 1.23
Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas. Neuro Oncol (2012) 1.19
Exomic sequencing of four rare central nervous system tumor types. Oncotarget (2013) 1.17
Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. Proc Natl Acad Sci U S A (2012) 1.15
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. BMC Cancer (2014) 1.14
Regulated temporal-spatial astrocyte precursor cell proliferation involves BRAF signalling in mammalian spinal cord. Development (2012) 1.13
Genome wide copy number analysis of paediatric Burkitt lymphoma using formalin-fixed tissues reveals a subset with gain of chromosome 13q and corresponding miRNA over expression. Br J Haematol (2011) 1.12
Increased microglia/macrophage gene expression in a subset of adult and pediatric astrocytomas. PLoS One (2012) 1.11
Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas. J Mol Diagn (2011) 1.11
Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma. Nat Rev Cancer (2014) 1.10
Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies. Am J Med Genet C Semin Med Genet (2011) 1.10
Pediatric high grade glioma: a review and update on tumor clinical characteristics and biology. Front Oncol (2012) 1.10
Overexpression of insulin-like growth factor 1 receptor and frequent mutational inactivation of SDHA in wild-type SDHB-negative gastrointestinal stromal tumors. Genes Chromosomes Cancer (2012) 1.08
Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas. Curr Cancer Drug Targets (2010) 1.07
Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRα/β. Mol Cancer Ther (2011) 1.05
To BRAF or not to BRAF: is that even a question anymore? J Neuropathol Exp Neurol (2013) 1.04
PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome. Neuro Oncol (2012) 1.03
PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma. Brain Pathol (2013) 1.00
The combination of novel targeted molecular agents and radiation in the treatment of pediatric gliomas. Front Oncol (2013) 0.98
MYB upregulation and genetic aberrations in a subset of pediatric low-grade gliomas. Acta Neuropathol (2010) 0.96
Analysis of the BRAF(V600E) Mutation in Central Nervous System Tumors. Transl Oncol (2012) 0.95
Cancer susceptibility syndromes in children in the area of broad clinical use of massive parallel sequencing. Eur J Pediatr (2015) 0.95
Clinical, radiological, histological and molecular characteristics of paediatric epithelioid glioblastoma. Neuropathol Appl Neurobiol (2014) 0.92
Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma. Clin Cancer Res (2013) 0.92
Pilocytic astrocytoma: pathology, molecular mechanisms and markers. Acta Neuropathol (2015) 0.91
Comparative oncology: what dogs and other species can teach us about humans with cancer. Philos Trans R Soc Lond B Biol Sci (2015) 0.91
BRAF-V600E mutation in pediatric and adult glioblastoma. Neuro Oncol (2013) 0.90
OLIG2 is differentially expressed in pediatric astrocytic and in ependymal neoplasms. J Neurooncol (2010) 0.89
High-throughput microRNA profiling of pediatric high-grade gliomas. Neuro Oncol (2013) 0.89
Pathological and molecular advances in pediatric low-grade astrocytoma. Annu Rev Pathol (2012) 0.87
Molecular inversion probe analysis detects novel copy number alterations in Ewing sarcoma. Cancer Genet (2012) 0.87
Will kinase inhibitors make it as glioblastoma drugs? Curr Top Microbiol Immunol (2012) 0.87
A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas. Neuro Oncol (2017) 0.86
Genotype-dependent cooperation of ionizing radiation with BRAF inhibition in BRAF V600E-mutated carcinomas. Invest New Drugs (2013) 0.86
Pediatric low-grade gliomas: how modern biology reshapes the clinical field. Biochim Biophys Acta (2014) 0.86
An inexpensive, specific and highly sensitive protocol to detect the BrafV600E mutation in melanoma tumor biopsies and blood. Melanoma Res (2010) 0.85
EGFR blockade prevents glioma escape from BRAFV600E targeted therapy. Oncotarget (2015) 0.84
Intramedullary pilomyxoid astrocytoma with intracerebral metastasis exhibiting oligoden-droglioma-like features. Rare Tumors (2012) 0.83
Tumor location, but not H3.3K27M, significantly influences the blood-brain-barrier permeability in a genetic mouse model of pediatric high-grade glioma. J Neurooncol (2015) 0.83
Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma. J Neurooncol (2015) 0.83
Mutant BRAF induces DNA strand breaks, activates DNA damage response pathway, and up-regulates glucose transporter-1 in nontransformed epithelial cells. Am J Pathol (2012) 0.83
Type 1 insulin-like growth factor receptor targeted therapies in pediatric cancer. Front Oncol (2013) 0.83
Copy Number Alterations and Methylation in Ewing's Sarcoma. Sarcoma (2011) 0.82
Diagnostic application of high resolution single nucleotide polymorphism array analysis for children with brain tumors. Cancer Genet (2014) 0.82
Molecular markers in pediatric neuro-oncology. Neuro Oncol (2012) 0.81
Genetic variations in plasma circulating DNA of HBV-related hepatocellular carcinoma patients predict recurrence after liver transplantation. PLoS One (2011) 0.80
Adult pilocytic astrocytomas: clinical features and molecular analysis. Neuro Oncol (2014) 0.80
A Sequentially Priming Phosphorylation Cascade Activates the Gliomagenic Transcription Factor Olig2. Cell Rep (2017) 0.80
Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma. Acta Neuropathol Commun (2016) 0.80
The BRAF kinase domain promotes the development of gliomas in vivo. Genes Cancer (2015) 0.79
The molecular biology of WHO grade I astrocytomas. Neuro Oncol (2012) 0.79
BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas. Clin Cancer Res (2016) 0.79
Precise Detection of IDH1/2 and BRAF Hotspot Mutations in Clinical Glioma Tissues by a Differential Calculus Analysis of High-Resolution Melting Data. PLoS One (2016) 0.78
Molecular characteristics of pediatric high-grade gliomas. CNS Oncol (2014) 0.78
Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells. Cancer Res (2015) 0.77
Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model. Oncotarget (2016) 0.77
A preclinical study demonstrating the efficacy of nilotinib in inhibiting the growth of pediatric high-grade glioma. J Neurooncol (2015) 0.76
Model-Based Evaluation of Spontaneous Tumor Regression in Pilocytic Astrocytoma. PLoS Comput Biol (2015) 0.76
Something old and something new about molecular diagnostics in gliomas. Surg Pathol Clin (2012) 0.75
A novel canine kidney cell line model for the evaluation of neoplastic development: karyotype evolution associated with spontaneous immortalization and tumorigenicity. Chromosome Res (2015) 0.75
Pediatric Brain Tumors: Current Knowledge and Therapeutic Opportunities. J Pediatr Hematol Oncol (2016) 0.75
Acquired resistance to BRAF inhibition in BRAFV600E mutant gliomas. Oncotarget (2017) 0.75
Next generation sequencing as an aid to diagnosis and treatment of an unusual pediatric brain cancer. J Pers Med (2014) 0.75
Papillary glioneuronal tumors: histological and molecular characteristics and diagnostic value of SLC44A1-PRKCA fusion. Acta Neuropathol Commun (2015) 0.75
Inhibition of MEK confers hypersensitivity to X-radiation in the context of BRAF mutation in a model of childhood astrocytoma. Pediatr Blood Cancer (2015) 0.75
Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. Cancer Cell (2017) 0.75
Pediatric high-grade glioma: current molecular landscape and therapeutic approaches. J Neurooncol (2017) 0.75
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol (2008) 10.29
Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol (2008) 7.79
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol (2009) 7.73
Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res (2008) 6.44
Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature (2008) 4.24
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest (2008) 3.98
Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol (2009) 3.32
Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett (2009) 3.19
Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene. Brain Pathol (2008) 2.61
Allele quantification using molecular inversion probes (MIP). Nucleic Acids Res (2005) 2.46
Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma. J Neuropathol Exp Neurol (2008) 2.40
Genetic alterations in signaling pathways in melanoma. Clin Cancer Res (2006) 2.00
Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma. Neurology (2009) 2.00
Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort. J Neurosurg (2006) 1.93
Analysis of molecular inversion probe performance for allele copy number determination. Genome Biol (2007) 1.78
Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort. Cancer Res (2001) 1.45
Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations. Clin Cancer Res (1999) 1.23
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
Functional profiling of the Saccharomyces cerevisiae genome. Nature (2002) 36.10
Next-generation DNA sequencing. Nat Biotechnol (2008) 34.95
The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol (2006) 30.90
Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature (2010) 9.81
Induction of tumors in mice by genomic hypomethylation. Science (2003) 8.86
The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34
Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A (2005) 6.54
An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg (2011) 6.32
Subtypes of medulloblastoma have distinct developmental origins. Nature (2010) 5.94
miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med (2008) 5.91
Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci (2008) 5.89
Unique astrocyte ribbon in adult human brain contains neural stem cells but lacks chain migration. Nature (2004) 5.85
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Common developmental requirement for Olig function indicates a motor neuron/oligodendrocyte connection. Cell (2002) 5.64
Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol (2008) 5.55
Neural stem cells and the origin of gliomas. N Engl J Med (2005) 5.43
Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell (2002) 5.11
Chemogenomic profiling: identifying the functional interactions of small molecules in yeast. Proc Natl Acad Sci U S A (2004) 5.10
Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells. Cancer Cell (2008) 5.06
Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science (2011) 5.04
Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma. Cancer Cell (2008) 4.68
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst (2005) 4.63
Mouse brain organization revealed through direct genome-scale TF expression analysis. Science (2004) 4.55
Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron (2007) 4.47
International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res (2002) 4.27
Corridors of migrating neurons in the human brain and their decline during infancy. Nature (2011) 4.12
Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol (2005) 4.10
Glioma extent of resection and its impact on patient outcome. Neurosurgery (2008) 4.02
Functional outcome after language mapping for glioma resection. N Engl J Med (2008) 4.01
Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol (2002) 3.99
Multigene amplification and massively parallel sequencing for cancer mutation discovery. Proc Natl Acad Sci U S A (2007) 3.93
Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg (2003) 3.91
Nmyc upregulation by sonic hedgehog signaling promotes proliferation in developing cerebellar granule neuron precursors. Development (2003) 3.88
Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS One (2012) 3.74
PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol Cancer Res (2006) 3.72
Radiation-induced cognitive impairments are associated with changes in indicators of hippocampal neurogenesis. Radiat Res (2004) 3.53
Neurofibromatosis 2. Curr Opin Neurol (2003) 3.46
Astrocyte-specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures. Ann Neurol (2002) 3.37
Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci Signal (2010) 3.35
A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell (2010) 3.34
Radiation-induced impairment of hippocampal neurogenesis is associated with cognitive deficits in young mice. Exp Neurol (2004) 3.30
Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol (2011) 3.23
bHLH transcription factor Olig1 is required to repair demyelinated lesions in the CNS. Science (2004) 3.20
Criteria for the use of omics-based predictors in clinical trials. Nature (2013) 3.15
Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin Cancer Res (2006) 3.15
Patterns of care for adults with newly diagnosed malignant glioma. JAMA (2005) 3.08
Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol (2007) 3.07
Neurofibromatosis type 1 revisited. Pediatrics (2009) 3.06
Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer (2004) 3.05
Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin. Cancer Res (2007) 3.05
Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1. Ann Neurol (2014) 3.01
Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS. Genes Dev (2009) 2.96
Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. Clin Cancer Res (2007) 2.94
Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol (2008) 2.92
Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol Cancer Ther (2007) 2.89
High gamma activity in response to deviant auditory stimuli recorded directly from human cortex. J Neurophysiol (2005) 2.88
The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev (2013) 2.86
Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer (2009) 2.77
Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol (2007) 2.75
Pten loss causes hypertrophy and increased proliferation of astrocytes in vivo. Cancer Res (2004) 2.75
Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol (2008) 2.71
Multiplex amplification of all coding sequences within 10 cancer genes by Gene-Collector. Nucleic Acids Res (2007) 2.70
Glioma stem cells: a midterm exam. Neuron (2008) 2.69
Categorical speech representation in human superior temporal gyrus. Nat Neurosci (2010) 2.67
The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas. J Neuropathol Exp Neurol (2004) 2.66
Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation. Mol Cell Biol (2002) 2.65
Neurofibromin regulation of ERK signaling modulates GABA release and learning. Cell (2008) 2.65
Sox9 is required for determination of the chondrogenic cell lineage in the cranial neural crest. Proc Natl Acad Sci U S A (2003) 2.64
Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol (2003) 2.63
Axin2 as regulatory and therapeutic target in newborn brain injury and remyelination. Nat Neurosci (2011) 2.61
Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype. Neuro Oncol (2007) 2.56
Regional astrocyte allocation regulates CNS synaptogenesis and repair. Science (2012) 2.53
Syngeneic mouse mammary carcinoma cell lines: two closely related cell lines with divergent metastatic behavior. Clin Exp Metastasis (2005) 2.52
Development of mice expressing a single D-type cyclin. Genes Dev (2002) 2.43
Contribution of Notch signaling activation to human glioblastoma multiforme. J Neurosurg (2007) 2.43
Functional mapping-guided resection of low-grade gliomas in eloquent areas of the brain: improvement of long-term survival. Clinical article. J Neurosurg (2010) 2.42
Hedgehog and PI-3 kinase signaling converge on Nmyc1 to promote cell cycle progression in cerebellar neuronal precursors. Development (2003) 2.42
Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res (2010) 2.41
Small-molecule inhibitors reveal multiple strategies for Hedgehog pathway blockade. Proc Natl Acad Sci U S A (2009) 2.41
CNS-resident glial progenitor/stem cells produce Schwann cells as well as oligodendrocytes during repair of CNS demyelination. Cell Stem Cell (2010) 2.40
Cardiovascular disease in neurofibromatosis 1: report of the NF1 Cardiovascular Task Force. Genet Med (2002) 2.39
A human-like senescence-associated secretory phenotype is conserved in mouse cells dependent on physiological oxygen. PLoS One (2010) 2.38
Genome-wide requirements for resistance to functionally distinct DNA-damaging agents. PLoS Genet (2005) 2.32
Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res (2003) 2.30
Astrocytes and disease: a neurodevelopmental perspective. Genes Dev (2012) 2.28
A prospective study of total gastrectomy for CDH1-positive hereditary diffuse gastric cancer. Ann Surg Oncol (2011) 2.27
Profile of daily life in children with brain tumors: an assessment of health-related quality of life. J Clin Oncol (2005) 2.26
Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity. J Neurosurg (2003) 2.24
Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts. Neuro Oncol (2009) 2.23
Dlx1 and Dlx2 control neuronal versus oligodendroglial cell fate acquisition in the developing forebrain. Neuron (2007) 2.23
Comanagement of surgical patients between neurosurgeons and hospitalists. Arch Intern Med (2010) 2.22